Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,867 JPY | +1.81% | +4.56% | 0.00% |
05-06 | Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints | MT |
05-06 | UK Tribunal Greenlights GBP790 Million Lawsuit vs Prysmian, Nexans, NKT | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 2.15B | |
+15.65% | 339B | |
+12.06% | 73.83B | |
-7.08% | 68.53B | |
+1.15% | 30.21B | |
+25.53% | 24.26B | |
+9.84% | 14.14B | |
+20.37% | 9.31B | |
-4.07% | 6.73B | |
+3.57% | 4.82B |
- Stock Market
- Equities
- 141A Stock
- News Trial Holdings Inc.
- Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'